Impact of a transition program with navigator on loss to follow‐up, medication adherence, and appointment attendance in hemoglobinopathies

Brooke Allemang(University of Toronto), Kevin H.M. Kuo(University Health Network), Colleen Johnson(University Health Network), Isaac Odame(Hospital for Sick Children), Geetha Mukerji(Women's College Hospital), Melina Cheong(University of Toronto), Patrina Cheung(University of Toronto), Kate Allan(Waitemata District Health Board), Richard Ward(University of Tennessee Health Science Center), Suzan Williams(Hospital for Sick Children)
Pediatric Blood & Cancer
May 2, 2019
10.1002/pbc.27781
Cited by 58

Related Papers

Hydroxycarbamide versus chronic transfusion for maintenance of transcranial doppler flow velocities in children with sickle cell anaemia—TCD With Transfusions Changing to Hydroxyurea (TWiTCH): a multicentre, open-label, phase 3, non-inferiority trial
|The Lancet|2015|518
A Phase 3 Trial of Luspatercept in Patients with Transfusion-Dependent β-Thalassemia
|New England Journal of Medicine|2020|320
Online haemodiafiltration: definition, dose quantification and safety revisited
|Nephrology Dialysis Transplantation|2013|256
Clinical spectrum of pyruvate kinase deficiency: data from the Pyruvate Kinase Deficiency Natural History Study
|Blood|2018|165
Safety and Efficacy of Mitapivat in Pyruvate Kinase Deficiency
|New England Journal of Medicine|2019|162